Venture Forum 2007

The Venture Forum is Proudly Produced by

Keynote Speakers

Vinod Khosla
Founder
KHOSLA VENTURES

In conversation with

Matthew Bishop
Chief Business Writer
THE ECONOMIST

Steven Burrill
CEO
BURRILL & COMPANY

Henry Chesbrough
Executive Director, Center for Open Innovation
UC BERKELEY

In conversation with

Scott Horsley
Business Correspondent
NATIONAL PUBLIC RADIO

William O'Brien
Senior Vice President, New Listings
NASDAQ STOCK MARKET INC.

Advisory Committee

Corporate Advisors

VC Advisors

Larta Institute Overview

Presenting & Exhibiting Companies

PAVILIONS

East Coast
Korea Pavilion
Midwest Pavilion
New Zealand
NIH
Northern California
Russia/Ukraine
Southern California
Taiwan
Tech Transfer Pavilion
West Coast

East Coast

Kibow Biotech Inc
Kibow Biotech has developed an oral probiotics product formulation (Kibow Biotics®) for uremic toxin removal in kidney failure patients. Through the bowel-based concept of “Enteric Dialysis™”, the product has the potential to delay the onset of dialysis or reduce the frequency in existing patients. Its efficacy in cats and dogs with renal failure has been clinically validated and licensed to Vetoquinol USA Inc (renamed “Azodyl”). Pilot-scale human clinical trials are currently in progress in USA, Canada, Mexico and Argentina. In addition, several related dietary supplement products targeted at metabolic syndrome condition are also marketed in USA.

Synergy Biopsy LLC
Synergy Biopsy LLC, will be formed upon funding for the commercialization of biopsy devices patented by Bioengineering Consultants Ltd. An innovative biopsy device has been designed, manufactured, clinically tested in animals and humans, patented, and FDA approved (510K) through an NIH SBIR Phase II grant. The core technology is a fully automated biopsy system for obtaining a soft tissue specimen and delivery of a material into the biopsy track for preventative measures, such as a hemostatic agent (liver, kidney), marker (breast), or chemotherapy material (kidney, liver, prostate, lung).

Korea Pavilion

Any Fill
AnyFill provides one solution of the world's first intelligent speed charger, covering over 99% of cell phone batteries worldwide any type, anytime, and anywhere. Increase in power consumption and limitation of battery capacity, in using mobile devices equipped by more advanced technologies, require significant demand for speed charging solution that is not being satisfied in the current market situation. AnyFill have already exported the products over 30 countries worldwide. The product can be utilized as a customer service facility or a marketing tool.

AnyFill seeks funding to develop a new product line for home and personal applications and global marketing.

Innovation & Ventures, Inc.
Innovation & Ventures (“InV”) is a Technology Business Incubation company with a number of breakthrough technologies and start-ups in its portfolio. One of its portfolio technologies in the area of clean technology produced “Plasma Burner” to be a part of DPF (Diesel Particulate Filter). DPF is a critical device to filter out pollutants generated from diesel engine vehicles. However, its function is limited to satisfy the relevant air quality regulations, which are being tightened internationally. InV's Plasma Burner provides a solution by immediately heating the filter to purify the exhaust gas, working effectively with DPF. InV is seeking business partnering with companies, potentially in the automotive parts industry, to expand its market globally and contribute to cleaner environment.

Panagene
Panagene produces peptide nucleic acid (PNA) and provides PNA microarray technology. Panagene is the exclusively licensed provider of custom PNA worldwide. Panagene provides any quantity of PNA using its patented technology. PNA is an artificial DNA analog, chemically and biologically stable; and binds to DNA/RNA more strongly and more specifically than DNA. Panagene developed PNA microarray with better specificity, better sensitivity, and longer shelf life (3 months at room temperature) than DNA-based microarray. Reliable SNP detection of HBV and genotyping of HPV were demonstrated. Panagene can develop custom PNA microarray using customers' diagnostic content.

Midwest Pavilion

MicroTransponder, LLC
MicroTransponder, Inc. is seeking to commercialize a new approach to pain management using the MicroTransponder System. The technology portfolio consists of a wireless micro-system (“the platform”) that can interface with peripheral nerves and a host of biochemical micro/nano- sensors (“sensors”). The company has an initial seed round investment and expects to derive significant revenue from STTR and SBIR applications filed in 2007. The company expects to deliver an acceptable FDA approved prototype by mid 2008 under a 510k application.

mVerify Corporation
mVerify has achieved round exit milestones: shipped product, significant traction, and an effective and proven team. Our entry level product is successfully competing with the best that our competitors can offer -- despite the fact that while they have received over $70 million of institutional funding, we have bootstrapped. Current customers include Motorola, PCTEL, Hand Held Computers, Accenture, Survey Lab, and SAIC. We are seeking our first institutional investment to achieve the dominant position in a hot and evolving B2B space, driven by the global growth in mobile technology.

New Zealand

Auckland UniServices
Auckland UniServices is the commercialisation arm of The University of Auckland, one of the Top 50 Universities in the world. We generated over US$50m last year, in 27 countries. Auckland UniServices is the largest provider of research to the Light Metals Smelting industries. We specialize in Molecular Biodiscovery and Drug Development - 13 compounds in the clinic, High Power Induction Power - transmitting kilowatts of contact less power to multiple outlets at the same time, BioEngineering - modelling whole body function for better medical devices, surgery, ergonomics and gaming applications, and Polymer Electronics and Nanotechnology. We aim to meet companies and investors looking to develop solutions in the areas above.

Canterprise
Canterprise is the Technology Transfer Office of the University of Canterbury. We translate innovations into commercial reality. Canterprise works closely with both New Zealand and international companies in the high tech sectors with the aim of contributing significantly to job and economic growth. We have a range of technologies to showcase and are interested in making industry and investor contacts in the areas of biotechnology, software engineering, bioengineering, nanotechnology, electronics and electrical engineering. Canterprise is developing a proven record of commercialising novel intellectual property, generating financial wealth for all stakeholders.

Living Cell Technologies Limited
Using pigs isolated for 200 years on a Sub-antarctic Island and screened for xenotic viruses, Living Cell Technologies (LCT) has developed for type 1 diabetes an encapsulated pig islet cell transplant (DiabeCell®) that does not require immunosuppressants. This lead product is patented and manufactured under GMP and enters clinical trials in 2007. The 10 year survival of transplanted cells from a DiabeCell® prototype in a human has been reported. DiabeCell® and other developing products including neurotrophin-secreting cells for Huntington's disease, stroke and hearing loss, are available for licensing. LCT's marketing of biocertified pig tissues and clinical program are at the stage for further capital investments.

Methodware
Methodware markets enterprise risk management and internal audit software to companies, financial institutions and government bodies worldwide. It competes in the growing market for governance, risk management and compliance software (GRC). Methodware products are market leading with clients including Lloyd's of London, Halliburton, Bristol Myers Squibb and McCain Foods. The Group is currently headquartered in New Zealand with offices in North America and Europe. Methodware is 100% employee owned, profitable, with zero debt and over 1500 customers. Methodware is seeking an investor(s) to provide US$ 3 million in growth capital to drive further penetration of the US market.

Nano Cluster Devices Ltd.
Nano Cluster Devices Ltd has developed a platform technology for the creation of self-assembled nanowires. Featured at SEMICON West 2005, our process enables scalable manufacture while competing techniques are limited by the inherent difficulty of manipulating their nanowires into real devices. Our patented technology enables order of magnitude advancements in many industries e.g. integrated circuits, communications, but we have chosen to focus initially on gas sensors where nanowires give faster response times and lower detection limits than conventional sensors. We are seeking strategic partners who can offer access to markets and who are keen to benefit from this disruptive technology.

Otago Innovation
A wholly-owned subsidiary of the University of Otago, Otago Innovation Limited is charged with exclusive responsibility for the commercialisation of Intellectual Property arising from research within the University. New Zealand is an untapped source of leading medical research and biotechnology innovation with the highest rate of publications per research dollar spent in the world (National Bibliometric Report - Ministry of Research, Science and Technology, 2004). Otago Innovation Limited is your gateway to the world class research at the University of Otago. The University of Otago is the most research intensive University in New Zealand. (Ministry of Research Science and Technology: Research and Development in New Zealand - A Decade in Review). We seek alliances with providers of 'Seed Funding', Venture Capital Providers, Licensing Partners, and commercial partners with expertise and experience in product related industries. Please contact us for further information about our available technologies for licensing and investment at enquiries@otagoinnovation.com.

RoamAD
RoamAD (est. 2001) supplies converged wireless networks to the citywide Wi-Fi and public safety markets. The company has proven technology and an existing global customer base. RoamAD's wireless networking software platform operates on open architecture hardware allowing its solution to be the most cost-effective, flexible and upgradeable on the market today. RoamAD customers include ISPs, cities, universities and public safety agencies. The company licenses its software via a channel model whereby OEM partners supply the hardware to integrators who add RoamAD's software and deploy the networks. RoamAD has a global pipeline of opportunities in a market that is growing at over 100% YoY. The company's revenue growth rate is outpacing that of the market. RoamAD is seeking both investment and partners to expand sales and marketing, attract new partners and accelerate ongoing research and development.

WaikatoLink
WaikatoLink is the technology transfer office of the University of Waikato, New Zealand. The University's areas of research strength include the molecular biosciences, chemistry, computer science, machine learning, GPS, mathematics, and engineering and technology. WaikatoLink ranks within the top 3% of university technology transfer offices (based on AUTM 2004 benchmarking). Recent start-up success stories include ZyGem (biotechnology; DNA extraction technologies), Ectus (ICT; e-learning software), Endace (ICT; hardware acceleration and network interface technology) and Titanox (new materials; titanium powders). WaikatoLink is currently looking for partners or investors for technologies including novel anti-infective agents, sustainable materials, titanium alloys, xenograft materials, 3-D imaging and automation software.

Zephyr Technology Ltd.
Zephyr Technology is a global leader in the use of Smart Fabrics for non-invasive vital sign monitoring and force detection. The company has used the technology across applications ranging from war fighter combat casualty care and body armor impact sensing to diabetic foot ulcer detection. It has been awarded contracts with the U.S. DOD based on in-field efficacy, product scalability and price point. Zephyr is looking for strategic investors with networks and relationships in defense. Equity injection will complete R & D, finalize patent portfolio and finalize commercial delivery.

NIH

AbleLink Technologies, Inc.
AbleLink Technologies™ has pioneered technologies which maximize independence and reduce costs for individuals needing specialized supports to live independently. The HomeLife Technology Suite TM delivers easy to use health care instructions using text, video and audio; provides automated reminders to take medications or perform exercises; tracks activity; and remotely communicates health information. This system enables seniors, their family members or home health care providers to perform health care tasks more accurately, using a unique person-centered approach which does not yet exist in the industry. AbleLink is seeking expansion funding, strategic partners and home health care organizations interested in cost-effective strategies for serving the expanding senior population.

Advanced Liquid Logic
Advanced Liquid Logic's digital microfluidics is a lab-on-a-chip technology based on direct, programmable manipulation of discrete droplets using electrical fields. It enables complex liquid handling to be implemented in software with no pumps, valves, or pipes. The Company has implemented rapid and sensitive clinical chemistry and immunoassays on chip and has demonstrated the feasibility of PCR and DNA sequencing. Ultimately complex test panels will be performed on low-volume samples with a PDA-like instrument. The Company has the team (10 PhD's) and the patent position (30 patents issued or pending) to succeed and seeks partners to take products to market.

Advantagene
Progression and recurrence after initial cancer therapy is a key underserved and unmet medical need. Advantagene is focused on addressing this need through simple products that improve the outcome of standard radiation, surgery or chemotherapy. Advantagene's lead technology, Gene Mediated Cytotoxic Immunotherapy (GMCI™), generates a patient-specific response from a non-patient-specific product. It generates an in-situ tumor-specific vaccine for a targeted, systemic response against residual tumor cells or occult micrometastases. GMCI™ can be applied to a variety of tumor types. Advantagene has positive results from a completed Phase 2 and multiple Phase 1 human clinical trials.

Advitech, Inc.
Advitech, Inc. is a company created to develop technology to prevent spatial disorientation and motion sickness. The company has a product specifically for the aviation industry (i.e. the Avionix device), and a product for other applications where individuals have hypersensitivity to motion sickness (i.e. the X-Motion device). The target market is aviation, with the intent to improve safety and prevent the mishaps secondary to some of the illusions causing spatial disorientation. Hardware and software technology have been developed which provides the pilot with more visual information about his head and body position in space. The hardware is comprised of a heads up display system and the software utilizes an artificial horizon and other lines or symbology to display movement and spatial orientation. For military application, the software technology can be displayed in the standard HUD device to provide synergistic information about his or her orientation in space. Other flight personnel can benefit, because they frequently lack visual reference, as the device can assist them with orientation and prevent the ill effects of motion sickness. In environments where individuals may experience hypersensitivity to motion, such as on ships or traveling in closed vehicles, the technology can be of benefit to prevent motion sickness. While using the device, individuals can continue to perform at expected high levels, without experiencing the ill effects of a motion disturbance. It has proven to be of benefit in rehab therapy with vestibular conflicts and offers a unique opportunity to assist in the post re-entry rehabilitation of astronauts. The technology is very unique for prevention of spatial disorientation and would parallel the air bag development seen in the automotive industry.

America Living Well
America Living Well will become the leader in community-centric obesity initiatives improving the health of children and adults. ALW is a community health web portal, leveraging: proprietary and proven web-based health, nutritional and behavioral modification technology; a robust, scaleable, customizable online platform with social networking and local content; a rewards system fostering multi-channel revenue streams; the power of community (business and health system partnerships) achieving sustainable impact. A $500K NIH SBIR grant funded a prototype, Princeton Living Well. The company seeks funding for expansion. Five year goal - over 1000 communities generating significant revenue in multi-billion market.

Aphios Corporation
Aphios Corporation (www.aphios.com) is developing enabling SuperFluids technology platforms to improve the discovery of natural therapeutics and manufacturing of rare and complex bioactive molecules, the nanodelivery of small molecules and therapeutic proteins, and the inactivation of viruses in natural and recombinant biologics. SuperFluids are gases such as carbon dioxide and alcohols like ethanol which, when compressed, exhibit enhanced thermodynamic properties of penetration, selection, solvation and expansion. Utilizing these enabling technology platforms, Aphios is also developing enhanced therapeutics for the prevention and treatment of certain infectious diseases, cancers and CNS disorders from a unique library of marine microorganisms and medicinal plants.

Assenti
Assenti creates new therapeutic management techniques enabled by biosensors. Assenti is currently developing an intraocular pressure (IOP) monitoring system, small enough to be implanted into the eye. The information provided by this system improves glaucoma therapy and prevents blindness. Glaucoma is the second leading cause of blindness in the USA and causes $3 billion is excess costs for Medicare insurance. Assenti is in preclinical trials and seeks to raise $10 million in private equity investments for further system development, clinical trials, and market launch.

Behavioral Research, Inc
Behavioral Research, Incorporated (BRI) is a small, for-profit, woman-owned company founded by a M.D., MPH. BRI's mission is to enhance the well-being of individuals, families and communities through the development and distribution of innovative, customer-driven, research-based interventions in behavioral health. BRI's interactive, computer-based, Pregnancy Information Program (PIP), funded by NIH/NIDA, is directed at the needs of pregnant woman and their providers. The PIP has been shown to accurately identify behaviors that may adversely affect birth outcomes, engage respondents in making positive changes, provide a powerful timesaving tool for busy clinicians and ultimately save money.

BioElectroMed
BioElectroMed is a small biotech company developing medical devices for the diagnosis and treatment of skin disease. Our first product is the Bioelectric Field Imager. This non-invasive, hand-held device provides an image of the electrical field in human skin that can be used to aid in the diagnosis of skin cancer. It will be very useful to the dermatologist who presently has no medical device to indicate if a lesion is malignant prior to biopsy. Since only about one suspicious lesion in 100 proves to be malignant, this device could greatly reduce the number of biopsies needed along with the scarring and histological lab processing costs that accompany them. The market for this device includes every dermatologist and many family practice doctors who examine patients daily for suspicious skin lesions.

BIOMEC Inc.
BIOMEC INC, which began operations in 1998, is focused on the development and commercialization of innovative medical devices. One promising device that is being developed and is nearing commercialization is a low-power, lightweight, portable and non-invasive pneumothorax (collapsed lung) detector. This device fulfills a strong unmet need in the first responder markets, including EMTs, Emergency Physicians, as well as a large Military market. BIOMEC has built multiple prototypes and completed successful clinical testing on the device. BIOMEC is currently finalizing product development and preparing the regulatory trials. BIOMEC is currently seeking additional capital to complete clinical trials, obtain FDA approval and launch the commercial device.

Biomedica Management Corp
Since 1999, Biomedica Corporation, has focused on Research & Development of 1) next generation anti-ischemic anti-inflammatory agents (selectin blockers and TNF inhibitors), and 2) hemostatic agents for severe hemorrhage and trauma. The company has concluded preclinical studies on Neutrolide, an anti-ischemic selectin blocker and TNF inhibitor, and is now developing a library of anti-ischemic compounds based on Neutrolide studies.It has also developed ClotFoam, the first sealant for non-compressible hemorrhage.The company is seeking $2,000,000 in strategic partnerships and equity investment that will allow moving its technologies to the clinical phase.

Biomedical Enterprises Inc
Biomedical Enterprises has successfully tested the first needle ever designed for hemodialysis. When used as a venous needle, it has three jets which decrease the velocity and turbulence of the blood by >6 times and causes no recirculation of blood. When used as an arterial needle, it < recirculation. This needle increases the efficiency of dialysis, decreases damage and clotting of the vascular access, and pain and suffering of patients, increases revenue to providers, and decreases the cost of care. 300MM needles are used worldwide. Preclinical studies have been performed at Georgia Tech, U. Alabama and G.Washington U and clinical studies are being finalized. The Company is seeking funds to license and market the new needle.

BioSciCon, Inc.
BioSciCon is a small business, 2-15, woman-owned, medical device R&D company in the start-up, pre-sale phase, created by founders (medical doctors, academicians and scientists) around a patented biomarker-based technology that enables multiple new patents and medical devices to satisfy unmet needs at the cervical cancer market (3-5 billion in the US and 15-20 billion worldwide in 2010). The company is seeking financial partnership or investment in a tiered business plan from 100 K to 10 million dollars to bring these multiple devices (FDA class 1, 2 and 3) to the national and international sales. Financial projections (including pre-money cost of 6.5 million and raising) suggest a fast return, break-even-point in 1-2 years of sale, and multiple (10 and more) returns after 5 years of sale or after a modest market penetration of 5%.

Biosome, Inc.
Biosome, Inc. is a biotechnology company that is founded upon an innovative nanoparticle based detection technology with applications in drug discovery, medical diagnostics, and pathogen detection. Biosome is initially focused on providing products to evaluate the “drug-like” properties of compounds (e.g., solubility, membrane affinity, tissue distribution, oral bioavailability) to predict whether or not potential drugs will reach their target in humans. Biosome products will greatly reduce the costs of these evaluations and vastly increase their throughput. Later Biosomes® applications for other markets such as pathogen detection for food and water safety and biodefense will be developed.

Blaufuss Multimedia
Blaufuss Multimedia (http://www.blaufuss.org) has developed clinical simulators for health care trainees and professionals using actual patient data and custom animations. In this respect they are not simulations, but rather virtual presentations of actual patients—which we call Virtual Patient Examinations (VPEs). Blaufuss will offer VPEs as site licenses to Medical Devices and nursing schools on a per-seat basis. The programs rely on existing IT infrastructure, for economical distribution, but provide the first reproducible, objective, and realistic training that has proven efficacy in controlled trials.

BlueSky Designs, Inc.
BlueSky Designs develops assistive technologies that enable people with and without disabilities to do things more easily, with increased independence. Innovative mounting and positioning technologies provide secure locking, easy access, and repositioning of equipment, including mobile applications. Key innovations include customizable secure locking positions and low effort unlocking and repositioning of devices, with limited dexterity required. The modular system includes single or multi-arm configurations, friction and tilt adjustment, quick release attachments, and various bases. Applications include positioning devices for vehicles, wheelchairs, workstations, manufacturing, laboratories, lighting, nursing homes, and hospitals.

Caregiver Technologies, Inc.
Caregiver Technologies develops and markets distance caregiving technology called AttentiveCare that allows family caregivers to provide care over the Internet. Whether you're a block away or a world away, with AttentiveCare, you can be there for your loved one. AttentiveCare provides a cost-effective intervention alternative for caregivers caring for aging loved ones. With AttentiveCare, caregivers can improve care, enhance the quality of life, reduce caregiving costs and enable loved ones to stay independent longer and age in-place, where they are happiest and want to stay. The company's technology is helping shape the future of caregiving.

CHA Corporation
CHA Corporation is a small R&D company that has developed a unique mobile system to recover organic solvents that are removed from an air-stream via Granular Activated Carbon (GAC). The GAC is not degraded in the process, so it can be returned to the adsorption system. The intended markets are existing GAC adsorbers and catalytic oxidizers (CatOx) used in VOC abatement. Adsorption system operators will realize economic benefits where GAC transportation and disposal costs are high. Customers evaluating CatOx will see a benefit by being able to implement GAC adsorption on higher concentration streams, eliminating the need for supplemental fuel.

Children's Progress, Inc.
Children's Progress, Inc. (CPI) aims to improve early childhood education through the use of classroom technologies. CPI was founded at Columbia University and has received grants from the National Institutes of Health, the National Science Foundation, and the US Department of Education to develop several new technologies for assessment and instruction for children in pre-kindergarten through third grade. In particular, CPI has developed and patented new methods for assessment that provide teachers and administrators with valuable insights about specific deficits that children might have and provides intervention protocols to help correct these problems. Working with MIT, CPI has developed and patented innovative methods of vision and hearing evaluations that can be administered over a computer and combined with our academic assessment - thus allowing schools to examine the causes of potential learning deficits (e.g., if a difficulty with phonemic awareness is attributable to a hearing deficit). CPI is currently expanding their product line to include educational technologies for the home retail market - thus giving parents the ability to identify potential academic and sensory problems early and correct them before the child enters kindergarten. The CPI assessments have been bought and are currently in use by over 200 schools across the country with several new clients signing on for the upcoming academic year. The company is seeking outside investment to expand the product line to additional markets.

CleveMed
CleveMed develops instrumentation with miniaturized telemetry and biomedical signal processing for the neurology and rehabilitation markets, with particular focus on movement disorders, clinical sleep, and CNS research. In alignment with corporate focusing, CleveMed is offering strategic partnership and licensee opportunities for a number of technologies including: Pressore Step™ (pressure based stepping and standing activity monitoring system), Heart Doc™ system (high resolution, long-term Holter monitor with wireless data transfer capabilities), KinetiSense™ (biokinematic monitor for movement disorders), Flocel™ (dynamic in vitro blood-brain barrier model), and a quad-band radio module (900MHz, 2.4GHz, and both WMTS bands) for OEM technology integration.

Clonex Development, Inc.
Clonex Development, Inc. (CDI), a privately held S corporation, was founded by Thomas Primiano, Ph.D., currently serving as President and Chief Executive Officer April 2000. CDI leases 2800 SF of laboratory space at the TEC Center in Madison, WI. CDI currently employs seven full and part-time scientific, business and administrative professionals. CDI genetically engineers cell lines to conditionally shift from replicative to production mode (RP Shift®) by entering premature senescence. RP Shift® routinely increases the production of protein from fibroblast, Chinese hamster ovary, mouse myeloma, and hybridoma cells by 5-10-fold in laboratory scale culture systems.

COE CARE.COM
COECare provides information technology solutions at the point of care to enhance the quality of care in cardiovascular & orthopedic medicine. COECare identifies unique value propositions within the quality of care space and develops the technology to realize that value. These value “targets” include under-penetrated markets for device and pharmaceutical companies, continuous quality improvement, and patient/provider education. The company's NIH-funded Cardiac Goal Program, its most advanced product, targets “Class I” recommended therapies combining computerized decision support, real-time quality monitoring, and patient education into a single, “point and click” application. The Cardiac Goal Program, currently in use at 2 hospitals with invasive cardiac programs, is linked to the hospital's laboratory information system, minimizing the time required for data entry and obviating the need for a comprehensive electronic medical record. COECare's marketing plan targets cardiovascular device companies along with hospitals. These two market segments stand to derive significant revenue from COECare's novel solution to the “quality gap” in the under-penetrated ICD market through increased implantation of “Class I” recommended devices with the implementation of the Cardiac Goal Program.

Cognitive Pharmaceuticals, Ltd.
Cognitive Pharmaceuticals, Ltd. (Cognitive) develops new drugs for brain disorders, including Alzheimer's disease (AD) and schizophrenia. The company's lead compound CDD-0102 reverses memory deficits in an animal model of AD, reduces the formation of toxic proteins and protects cells. Based on this, CDD-0102 will have unique benefits in treating both the symptoms and underlying causes of AD. The company expects to file an IND application during 2007, and is currently completing the necessary preclinical studies and GMP manufacturing. Cognitive seeks a partner or equity investor to fund Phase I and II clinical trials for its AD product and position the company for commercial success.

Condax Medical Products LLC
Condax Medical Products LLC focuses on developing patented safer-sex and erectile dysfunction technologies. Two products are already FDA 510(k) approved. These products and others in its pipeline have been clinically tested in research supervised under National Institutes of Health (NIH) protocols. Newly patented products enable and support erectile functioning without needing any invasive techniques or pharmacological preparation. Instead, only natural pressure is utilized. Test results indicate that both partners experience greater sexual satisfaction using this technology.Other condom applicator products permit condoms to be instantly applied (less than one second), using only one hand, and always in the correct-way-on orientation.

CorTechs Labs, Inc
CorTechs Labs develops and deploys computer-aided diagnostic (CAD) products for analyzing magnetic resonance images (MRIs). Neurodegenerative disorders such as Alzheimer's Disease produce changes in the brain that can be measured with MRIs. By automating MRI analysis methods, CorTechs' neuro-CAD products decrease costs and improve reliability for quantifying such abnormalities. The tools provide sensitive imaging biomarkers that can reduce the expense and duration of clinical trials. Neurologists and neuroradiologists can also use our products to aid in the earlier and more accurate diagnosis of clinical conditions. We seek strategic partnerships and investments to help bring these unique technologies to market.

CPM Systems, Inc.
CPMS has developed a Web-based patient self-assessment system, called CarePrep, designed to support all medical and surgical care. Patients enter their own health data. Clinicians get alerts, summaries, and interpretations that jump-start the clinic encounter. CarePrep focuses on difficult cases who have multiple symptoms, psychosocial issues, disability, and high costs. CarePrep identifies difficult cases at the outset, allowing more cost-efficient team management and better outcomes. CarePrep also seamlessly implements Patient-Centered Quality Improvement and Research In Practice Settings, providing feedback about process and outcomes. CPMS seeks providers and payers interested in deploying CarePrep and validating its impact on quality and costs.

CYKE
CYKE has developed a multimedia health portal that provides guidance to parents dealing with the emotional problems of their children and gives kids a place to better understand their own feelings. For every parent that faces a toddler meltdown or troubled teenager, CYKE's premier Internet gateway presents the best standards of practice in pediatric mental health. On our website, we also showcase online games, cartoons, and reality videos in an interactive environment designed especially for kids. We seek funds and alliances to develop CYKE into a global brand recognized as the leader in pediatric mental health information and one that empowers the minds and hearts of children.

DCM Associates, LLC
DCMA, an online learning company, focuses on delivering critical workforce training for industries that deal with hazardous materials, a key to homeland safety. Ensuring that HazMat workforce training is available just-in-time, customized to the needs of workers, is the key to DCMA's offering. Our industry experts update highly interactive online e-Learning courses that fit into schedules anyplace, anytime--saving time and workforce training costs. A unique delivery system specifies the course, tracks performance, and maintains training records. DCMA seeks partnerships/funding to roll out proven courses. DCMA enjoys a unique position in the marketplace because HazMat/Dangerous Goods transport regulations are becoming global.

Eaker Epidemiology Enterprises, LLC
TalkToYourDoc is an Internet-based software tool that facilitates doctor-patient communication during office visits and encourages patient empowerment. The tool is disease-specific with a completed hormone replacement therapy application and additional modules for diabetes, hypertension, and heart disease under development. TalkToYourDoc uses patient input (personal risk factors and health history) to create a printable guide for doctor-patient discussion. The tool has been clinically proven to increase office visit efficiency, thereby reducing costs. Eaker Epidemiology Enterprises, LLC is seeking licensing partners such as health care organizations, point-of-care information vendors, and doctor or patient-networks to bring the TalkToYourDoc tool to doctors and patients. We seek primarily to ally strategically as well as to seek venture capital investment.

EcoArray, Inc.
EcoArray's mission is to bring gene microarrays to environmental toxicology and to provide a path to relate the environment to human health. We expect to extend our work with the EPA and researchers into the compound screening and environmental monitoring markets through our proprietary database of array results. Microarrays are faster and 30-50% cheaper than current methods. By operating at the genetic level, they promise to be the link between environmental toxins and human health. They are attractive to the compound screening market for broad, inexpensive initial screens and to environmental testing for both diagnosis and low-cost routine monitoring.

Epikeia Incorporated
Epikeia Incorporated is positioned to bring to market a pipeline of dermatology, cosmeceutical, pain management, and wound care products based on its polymer-based topical drug delivery technology. Epikeia products are applied directly to the skin as a liquid that rapidly dries to form a thin, transparent, barrier film. In contrast to creams or ointments that stay in contact with skin for only minutes, the Epikeia polymer film vehicle will remain intact on skin for many hours, providing sustained delivery of active compounds while maintaining barrier protection of the skin. Epikeia operates a FDA registered manufacturing facility and currently manufactures, packages and ships two cosmetic products.

Fox Learning Systems, Inc.
Fox Learning Systems, Inc. provides education for the most challenging and medically complex population, the frail and elderly. In the next two decades the population 65 years and older will increase by more than 76%. Fox Learning Systems (FLS) is poised to take advantage of the growing market segment of educating elder healthcare workers via e-learning, an opportunity spawned by need and federal regulation. Technology has become a more important part of the industry and the population growth curve needing elder healthcare is ready to explode. No product on the market today can compare with the “television-like” quality of our video streaming training. The Fox Learning Systems pricing structure is comparable to its competitors, giving FLS the leading edge because of the quality of the presentation and content. Product and market strongly positioned for strategic partnering.

Gamma Medica-Ideas, Inc
Gamma Medica-Ideas, Inc. specializes in creating medical imaging equipment based upon the latest radiation detection technology. GMI has expertise in design, fabrication, and packaging of semiconductor detectors such as cadmium zinc telluride (CZT). GMI is in two distinct markets in the medical imaging field: pre-clinical, multimodality (e.g., SPECT/CT) imaging and dedicated nuclear breast imaging. GMI leverages its detector engineering and image processing and display expertise into both markets. GMI works closely with luminary customer sites to implement new features and capabilities into its products.

Genome Data Systems Inc
Genome Data Systems, Inc., (GDS) has developed a cell-based, high content assay technology for drug discovery. GDS' GeneCardTM technology enables cell-based screening of candidate drugs using very small assay volumes in a controlled environment, saving customers expensive reagents and chemicals. Although currently focused on cancer, the GeneCardTM system provides high-throughput screening of compound libraries for novel therapeutics of other complex diseases such as diabetes and hypertension. Implementation of the GeneCardTM technology entails the use of GDS' unique add-on device to existing screening instrumentation. Located in Hamilton, NJ, GDS is seeking seed funding for the manufacture of its prototype devices and related peripherals.

HD technologies, Inc.
HD Technologies, Inc. engages in the research, development and marketing of innovative wavelength dispersive analyzer/detectors for the detection of x-ray fluorescence. These are tunable devices with excellent efficiency and superb energy resolution. As such, it will allow for very sensitive microanalysis and spectroscopy measurement using intense x-ray and electron beams. The products address a huge market ranging from synchrotron based spectroscopy and fluorescence analysis to Scanning Electron Microscopy. The sale of our first generation products has occurred recently. Significantly better products are in various stages of development. The company is seeking investment for the commercialization of the products

Healia, Inc.
Healia® is a next-generation, consumer health search engine that uses patent-pending algorithms and methods for machine assessment of content to generate high quality and personalized results. It is superior to competitors because it provides consistently high quality and personalized results, has “built-in” intelligence, and is extremely customizable. Healia empowers online publishers, healthcare organizations, and employers to provide high quality and personalized health information and targeted messages to their Website visitors, members, or employees. The search engine enhances consumer and health professional decision-making, improves educational efforts and consumer-directed care programs, and offers unparalleled, highly targeted marketing opportunities to advertisers and marketers.

HealthPoint Interactive
HealthPoint Interactive develops patient-centered learning resources delivered through multimedia, touchscreen kiosks. Randomized studies have validated the effectiveness of our kiosks, which led to several national awards and publications in major journals. We are poised to leverage our patient education model into a multilingual line of preventive health and self-care kiosks on cancer, diabetes, cardiovascular disease and nutrition. Deployment of our kiosks can result in sizeable savings for the health care industry. We are seeking strategic partnerships to expand our product line and gain access to national and global marketing and distribution channels to effectively reach hospitals and other healthcare institutions.

Herbst Research, Inc.
Herbst Research is dedicated to developing innovative high-tech solutions for biomedical applications. Our experience in electrical and biomedical engineering and our understanding of tissue culture and animal studies and clinical applications allow us to provide advanced technical solutions for the biomedical field.Our core technology enables product development for multiple applications, including intelligent electrical stimulation, automatic drug delivery systems, tissue regeneration, and diagnostics. Herbst Research builds on a strong IP portfolio and has received $5.5 million in NIH funding. The Company seeks strategic partners in various application areas and for licensing of its technology.

High Throughput Biology Inc.
The mission of High Throughput Biology Inc. is to become a leading global provider of integrated data management and analytics for the biomedical and healthcare industry. With strong focus on usability, scalability, and interoperability, our innovative software and algorithms empower all biomedical researchers and clinicians, regardless of their expertise in biocomputing, to intuitively manage, robustly manipulate, efficiently analyze, and securely share biomedical and clinical data. Our goal is to boost productivity, reduce cost, and empower scientists on what they do the best: advance science and improve people's life. HTB is currently seeking early-stage equity funding to commercialize the products.

Imaging Therapeutics, Inc.
Imaging Therapeutics, Inc., based in Foster City, CA, focuses on the development of novel low-cost imaging tests to assess bone structure for diagnosis and monitoring of osteoporosis. Osteoporosis is a major public health threat, affecting 44 million Americans who have the disease or are at increased risk.

Unlike current techniques, these tests can make screening more widely available and aid the physician in better identifying individual patients at risk of fracture. They can also be used as surrogate outcomes in pharmaceutical drug trials, in which they will help to significantly reduce the sample sizes currently necessary to determine drug efficacy.

InfoCulture
Human behavior that ignores the best knowledge is the greatest single detriment to public health, education and welfare. Past media campaigns to inform beliefs and norms have had mixed results. InfoCulture has developed a culture-centered informational media approach that diverges sharply from existing models. The first product, the feature film Euphoria deals with the devastating issue of substance abuse. Preliminary data indicates the product's potential to reverse the long-term failure rate of media interventions in this area. Several other products, all of which leverage the power of the Internet, are currently in development.

Inner Health, Inc.
Inner Health Inc. has developed and is improving its innovative sleep enhancement training technologies, using the latest 'Virtual Reality' sound technology and psychological techniques. These provides novel solutions to the problems of sleeplessness and fatigue due to insomnia, shiftwork or jet lag. This approach can also be used to simply enhance sleep for personal reasons or for stress management. The U.S. Air Force and National Institutes of Health Small Business Innovation and Research (SBIR) program awarded the Inner Health over $1.7 million to develop its technologies

Intelligent Optical Systems, Inc.
Intelligent Optical Systems, Inc. (IOS) is an R&D company developing cutting-edge technologies in optical sensing and instrumentation. The Spectroscopy and Physical Sensor division of IOS focusses on medical device development for diagnostic and monitoring applicationsbased on optical fiber devices.IOS drives innovative technologies through the development cycle all the way to independent spin-off companies that focus on optical product applications and setting up manufacturing and production of new products.

Interactive Drama Inc.
Interactive Drama Inc. has developed a unique interactive video method called virtual dialogue, which gives users the illusion of having a conversation with a real person in cyberspace. Over $3.5 million in federal R&D funds have been invested in this methodology. Experiments involving over 950 subjects - physicians, patients, students, and teachers - have demonstrated its acceptance and profound educational effects. An unlimited number of users can have simultaneous, face-to-face, individualized dialogues with a given expert, guaranteeing every user precisely the same opportunity to “meet” and learn from that expert, at negligible cost. The National Library of Medicine, Georgetown University Medical School, Mayo Clinic, and John Glenn NASA Research Center, are using the method.

IRIS Media, Inc.
IRIS Media specializes in the development, production and marketing of media-based training programs related to health and behavior. The company's research-based product line is targeted to professionals in K-12 education, special education, higher education, and parent education. Training is delivered on DVD and eDVD with accompanying print materials, and serves customers' needs for continuing education and professional development. IRIS Media is finalizing a technology platform that will support the online delivery of video-based professional training accredited by the University of Oregon. The company website is www.lookiris.com.

ISCHEM Corporation
ISCHEM Corporation (ISCHEM) provides products that save lives and dollars through advances in cardiovascular diagnostics. In 40% of people with cardiovascular disease, the first symptom of the disease is death. ISCHEM has created a patented product permitting clinicians and healthcare facilities to determine who is acutely “vulnerable” to heart attack and stroke. ISCHEM's product provides the means, for the first time, to noninvasively and unambiguously identify (and concurrently localize) a threatening cardiovascular problem before it unexpectedly kills or debilitates. ISCHEM has also developed a product that markedly improves long-term risk prognostication for cardiovascular disease, a product that enables improved targeting of preventive measures to those most in need, sparing healthcare dollars with equal saving of life; or sparing life with equal expenditure of healthcare dollars.

Life Recovery Systems HD LLC
Life Recovery Systems has developed an innovative system for rapidly cooling a patient's core temperature: the ThermoSuit® System (TSS). The TSS will allow medical personnel to rapidly cool patients in a variety of settings with an easy-to-use and non-invasive approach. The TSS is designed to save brain and heart tissue and thereby improve the quality of lives. FDA approval to market the product was received in September 2006. Research has proven that therapeutic hypothermia (patient cooling) can have a positive impact on cardiac arrest and post-arrest patients. There is also a strong belief in the medical community that hypothermia could have a positive impact on heart attacks, strokes and traumatic brain injuries. Therapeutic hypothermia is patient cooling designed to protect tissue from damage caused by lack of oxygen and to preserve organ function until a physician performs procedures and administers drugs to restore oxygenated blood flow to the patient. There is a strong market need for a non-invasive device that can rapidly cool patients who suffer these conditions. We have successfully Launched the product in US, Trained 20 sales representatives and cooled over a dozen patients in four clinical settings. We are awaiting CE Mark in Europe and approval to sell in Canada. We have a strong patent portfolio that covers both conceptual and functional elements of our design. Additionally we have significantly reduced the difficulties and problems associated with other non-invasive devices. Since the TSS is fast and easy to use, it can make therapeutic hypothermia available all at hospitals worldwide. We are currently pursuing additional indications and product extensions and add-ons and are seeking funding and corporate alliances to accelerate into the market.

Lifepharms
Natural products and their derivatives have supplied pharmaceuticals in every therapeutic area. Culturable bacteria and fungus have been the source organisms for many of these compounds. LifePharms' natural product collection consist of >20,000 extracts, 100,000 purified and semipurified compounds from over 30,000 field collected basidiomycetes and ascomycetes (mushrooms). Most of our collection is from unculturable species. Our compound libraries area rich source of novel compounds, many of then synthesized under conditions of environmental stress. LifePharms is presently screening this natural product library for novel anticancer and antiviral compounds. We are seeking strategic partners to discover lead compounds in additional therapeutic areas including antibacterial, immune suppressants, cholesterol lowering, etc. For more information see www.lifepharms.com.

MandalMed, Inc.
MandalMed is the first and only source of proprietary human Sertoli cells and is developing both cellular therapy products and reproductive function / toxicity assays for the diagnostic / research markets. A significant body of data shows that Sertoli cells reduce host rejection of allografted cells during transplantation and increase the growth of certain cells such as neurons. Potentially, these Sertoli cells have multiple treatment applications in important markets including Type 1 diabetes, neurodegenerative diseases, and infertility due to deficiency or malfunctioning Sertolis. MandalMed is seeking seed capital and to establish strategic alliances for development of cellular therapeutics.

Mealtime Partners, Inc.
Mealtime Partners, Inc. is the developer and manufacturer of the Mealtime Partner Assistive Dining Device. The Mealtime Partner is a new and innovative technology that permits individuals, who otherwise cannot feed themselves, to eat without assistance after they are provided with food. It will provide independence when eating for persons with impairments due to spinal cord injury, cerebral palsy, multiple sclerosis, stroke, muscular dystrophy, birth defects, and old age. The Mealtime Partner provides the foundation for a new industry serving the needs of the rapidly growing population of elderly and disabled individuals who are unable to eat independently.

Medical Decision Modeling Inc.
Medical Decision Modeling Inc.'s mission is to provide products and services that facilitate cost-effective healthcare decisions. MDM's core competency lies in the development of interactive software applications called medical decision models. These models clearly communicate the risks, benefits, and costs of competing courses of care for medical conditions. MDM's target markets include pharmaceutical companies, medical device manufacturers; and healthcare payers, providers, and patients. MDM's corporate objective is to be the world leader in the development and dissemination of medical decision models to payers (and those who market to them, e.g., pharmaceutical and device companies), providers, and patients.

MediSpin Inc.
MediSpin, Inc. is an innovative medical communications company consisting of a team of knowledgeable, experienced, creative professionals dedicated to meeting the educational, training, and marketing needs of diverse healthcare, pharmaceutical, and academic specialists. Currently, MediSpin, working with Duke University under NIMH Phase II grant funding, is developing an Internet-based software prototype designed to assist physicians who treat ADHD children to implement evidence-based treatment procedures. This product is designed to provide community physicians with tools that will allow them to efficiently, effectively, and economically (both in time and cost) treat ADHD children. It will also greatly enhance communication between the physician, parent and teacher.

Mi-Co
Mi-Co, the mobile data capture company, provides software to eliminate numerous pains of paper forms-based business processes. Mi-Co's enterprise Mi-Forms Software System provides flexible electronic forms design for data capture using digital ink and has proven capabilities for handwriting interpretation and verification, data validation and the communication of forms-based data. Mi-Forms supports Tablet PCs, Digital Pens, Pocket PCs, signature capture devices and industry standard software technologies. Mi-Co reaches historically paperwork intensive markets such as the healthcare and government sectors through a growing network of over forty channel partners. www.mi-corporation.com

MicroMRI Inc
MicroMRI aims to provide imaging-based monitoring tools which are non-invasive, accurate, readily-available and cost-effective. MicroMRI's current products deliver microscopic-level images of bone and cartilage architecture for arthritis and osteoporotic disease monitoring. The currently available tools with adequate specificity are invasive: bone biopsies and arthroscopies. MicroMRI delivers non-invasive methods to accurately evaluate these diseases. MicroMRI sells its systems for research and is the world's only company that provides research services for structural quantification of bone changes during drug treatment in humans for pharmaceutical and academic research. MicroMRI intends to obtain FDA clearance for its systems and market them in clinical markets.

Morphonix, LLC
For the past 17 years, Morphonix LLC has developed innovative programs in new media to better educate and support children. It has released award-winning, entertaining, immersive learning games that make the complex concepts of brain science fun for children and teens. From the acclaimed Journey Into The Brain (for ages 7-11) to the soon-to-be released Neuromatrix (ages 11-14), Morphonix is serving a critical market that everyone can relate to. The huge need for alternative, challenging tools to stimulate kids in schools and at home has put the focus on Morphonix, which now serves consumers at home and schools (with supplemental learning materials). Neuromatrix, bound to be a hit, includes a captivating story and game set in an immersive environment, allowing kids to use their brains to learn about the brain. Morphonix's video games are cool enough to play at home, smart enough to play at school. Morphonix seeks developmental and/or licensing partners to take the rich content and strong titles it has developed to a new level.

Nanoprobes, Incorporated
Nanoprobes researches and develops novel technology based on the use of metal nanoparticles as reagents for the detection and visualization of biological targets. Current commercial products include X-ray contrast agents for MicroCT and research, immunogold reagents and probes, combined fluorescent and gold probes, and ultrasensitive detection methods for in situ hybridization, microscopic and blotting applications. The company develops technology and reagents for medical imaging and the diagnosis of disease using nanoparticle-based contrast agents and markers, and is also engaged in the development of novel therapeutics based on the enhancement of other therapeutic modalities, such as radiation, by metal nanoparticle-based reagents.

Neurobiotex, Inc.
Neurobiotex is a science based company specializing in discovery and invention in the area of zinc in biology. Combining business and scientific expertise we have patents pending on products to measure, control and modulate free zinc. Our research tools, as well as our developing diagnostics and therapeutics focus on early detection and preventive applications in the areas of neurological diseases, cancer and diabetes. We believe this is the future of medicine and that development of our technology shall enhance economic development in our country while significantly decreasing healthcare expenditures.

NeuroScript
NeuroScript is the only company in the world developing and marketing PC software to record and automatically analyze handwriting movements. Our PC software (MovAlyzeR) requires only off-the-shelf hardware. MovAlyzeR makes the seemingly complex measurement and processing of pen movements easy to use after a brief learning period. Neuroscipt's target market consists of psychiatrists. MovAlyzeR can help them to better monitor and quantify medication side-effects which helps to reduce the risk of nervous system damage due to overmedication and which will significantly save health-care and insurance costs of psychiatric patients. Currently, MovAlyzeR is used by researchers in kinesiology, experimental psychology, psychiatry, neurology, occupational therapy, aging, handwriting instruction, child development, forensic handwriting analysis, computer science and by university students for their graduation and course projects. Although these markets are small, they will eventually spawn applications satisfying latent needs in several larger groups of health-care professionals or even the general public of consumers.

NexBio, Inc.
In recent years the world has witnessed the escalating outbreaks of avian influenza viruses in humans. The inadequacy of current prophylactic and therapeutic modalities has become all too clear. In response, NexBio, Inc. is developing broad-spectrum therapeutic and prophylactic agents to protect the public from all annual and pandemic variations of influenza, as well as from other life-threatening respiratory viral infections. Our mission is to develop novel, broad-spectrum prophylaxis and therapeutics for the prevention and treatment of serious or life-threatening human respiratory infectious diseases.

Nextek Mobility Corporation
Nextek Mobility Corporation has developed a new all-wheel drive powered wheelchair with a zero turning radius. The new technology is called PAWS or Parallel- All Wheel Steering and provides excellent maneuverability and incredible off-road performance. Potential customers include power wheelchair users who wish to access outdoor and rough terrain without sacrificing the maneuverability required indoors.

Nitrate Elimination Company, Inc
NECi, The Nitrate Elimination Company, Inc, is pioneering the migration of enzyme-based analytical methods from research and biomedical fields into the mainstream analytical chemistry community. NECi's introduction of recombinant nitrate reductase (NaR) has made enzyme-based nitrate analysis practical: NaR is produced in commercial quantities with consistent performance properties at affordable cost. NaR replaces the toxic cadmium reagents in use today for nitrate testing in water, public health, agriculture, industry, and the environment. Applications range from test kits for field use to reagents for commercial testing labs. NECi seeks partnering, distribution, and supplier agreements for bulk enzyme and/or for complete test kits.

Nonlinear Ion Dynamics, LLC
NID develops proprietary devices to efficiently enrich a full range of “stable isotopes”, which are highly-valuable special materials for medical (diagnostic & therapeutic), industrial and research applications. Currently, many highly-demanded stable isotopes are not available from existing technologies. For those that are available, most are very expensive, resulting in limited usages. In addition, there is currently no domestic “stable isotope” producer and most stable isotopes consumed in the US market are imported from foreign countries like Russia. NID provides solutions to all of the problems by producing a full range of stable isotopes inexpensively in the US. The competitive advantage of NID's proprietary technology has been successfully proven by a prototype. With $2.6 M funding from NIH and other resources, NID's 1st commercial device is expected to be completed in the end of 2007 and start commercial production in January, 2008. The company is seeking investment to construct a new larger-scale device to capture the more than $200M unmet market. NID's products are considered highly value-added “raw materials” for medical products and are not subject to FDA regulation.

Organizational Wellness & Learning Systems
Organizational Wellness & Learning Systems, Inc has developed IntelliPrev™, a patent-pending, web-based platform for HR professionals that enables them to monitor employee perceptions, assess corporate wellness needs, design science-based solutions, shop for wellness vendors, and access tools and training on critical tasks that directly affect their own professional success, including projecting and comparing ROI, securing executive buy-in, preparing their organizations for program delivery, and evaluating program success. IntelliPrev™ is currently seeking “smart” capital, key strategic relationships and one or two outstanding industry professionals to lead this division.

ORIGINUS, INC.
Originus Inc. is a biotechnology company found in 2001 by four internationally known scientists from the University of Michigan. With a focus in neuroscience, Originus supplies the Pharma/Biotech industry with high quality cell-based research results and assay products. We specialize in state-of-the-art solid phase transfection using STEP technology, a protein expression protocol, exclusively licensed from the University of Michigan. Using our expertise in complex biological systems, we develop transfection-based assays and functional screening technologies for cost-effective, accelerated, rational and predictive drug discovery. Originus Inc. is seeking Licensing and Partnering with pharmaceutical, biotech or supplier companies.

Phase V Pharmaceuticals, Inc.
Phase V Pharmaceuticals, Inc. develops new formulations for drugs used to treat central nervous system (CNS) injury. We focus on the special needs of 1.5 million people with a severe traumatic brain injury, spinal cord injury, or cerebral palsy. Our SBIR-supported product improves the care of patients with both spasticity (uncontrolled high muscle tone) and dysphagia (difficulty swallowing) by providing a liquid formulation of baclofen, the first line anti-spastic medication. Phase V's development pipeline addresses over $500 million of the $5 billion spent annually on drugs for this patient population.

Phoenix Biosystem, Inc.
Phoenix Biosystem is developing a proprietary integrated system for automated, small volume, blood sampling and analysis. The best-in-class nano volume sensor based technology provides a platform for highly accurate, cost effective, one step, painless, easy-to-use testing procedures. The product improves patient convenience by automating what traditionally has been a manual, multi-step process of lancing, blood droplet formation, and sample collection. Phoenix Biosystem's first product will address the unmet self-testing needs of diabetics. The diabetic patient population is stubbornly non-compliant for a combination of reasons including unawareness of the disease, general apathy, cost, and the inconvenience and pain of testing. Phoenix Biosystem's solution of painless, One Step, ease-of-use testing using a very fine lancet, very small drop of blood, and a cost effective automated one step operation will help improve patient compliance substantially. Phoenix Biosystem has raised funds in excess of $2.5 million and has established clinical feasibility of the technology. Phoenix Biosystem is currently seeking to raise $7 Million. The Company expects to use the proceeds to complete the product development and initiate FDA filing.

Physical Sciences
Physical Sciences's Inc (PSI) goal is to bridge the gap between the federal government and prime contractors in the research, development and deployment of technology for the U.S. Government. As a 33 year old company, PSI has an international reputation for technical excellence and innovation. We have successfully developed and transitioned advanced technologies to support the missions of the Department of Defense, NASA, NIH, and many commercial partners. We are dedicated to the role of applying scientific and engineering innovation to solve technological problems while simultaneously promoting internal product development and ultimate transition to government applications or commercial offering.

Phyto-Technologies, Inc.
Phyto-Technologies' Phyto B/P Profiling™ has successfully bridged the gap between the World's rich herbal wisdom and modern science. Now, therapeutic, cosmetic and supplement products with the reproducibility, quality control and intellectual property protection commensurate with modern drugs can be developed at a fraction of the latter's cost. Furthermore, conscientious and knowledgeable researchers and manufacturers who understand the importance of well-defined and appropriately characterized botanical starting materials for achieving reproducible research and quality products can benefit from our unique Representative Botanical Reference/Research Materials™ (RBRM™). We offer a variety of unique market-ready products, developed from our grant-supported research, for licensing and sale.

PinMed, Inc.
For the first time, the earliest signs of clinically significant changes, cardiac events or complications can be detected, flagged, and sent to medical professionals real-time using the PELEX (Personal Electrocardiographic (ECG) Expert System). This personalized network (proprietary technology) allows real-time wireless two-way data communication via cell phone, PDA, tablet PC, or computer. PELEX is the first all-in-one, miniaturized, intelligent, mobile system that can replace virtually all types of ECG tests. PinMed, its developer, is seeking partners/investors to launch PELEX, its first FDA cleared product, and develop other products based on proprietary personalized-network platform technology. www.pinmed.net

Planet Biotechnology Inc.
Planet Biotechnolgy seeks to extend the potential of monocolonal antibody products to the prevention and treament of infectious diseases affecting large populations. We produce monoclonal antibodies in genetically modified non-food non-feed plants (plantibodies). Our products are designed to prevent infection by viral and bacterial pathogens, such as Rhinovirus and Streptococcus mutans, and to prevent intoxication by bacterial toxins such as Botulinum Neurotoxin and Anthrax lethal toxin. Antibody production in plants allows rapid expansion of production capacity at low cost compared to antibodies produced in mammalian cell culture systems, making our system of plantibody production particularly suitable for profitably controlling multi-million patient infectious disease targets with multi-hundred million dollar markets in which the cost of therapy may be price sensitive.

Portland Bioscience
Portland Bioscience, L.L.C. products emanate from the company's fundamental knowledge base of DNA Multiplex Hybridization. Products include the Multiplex Hybridization Toolbox and corresponding experimentally derived Tandem Mismatch Thermodynamics Database. This technology is revolutionary in its comprehensive analytical approaches and thereby can be applied to significantly improve hybridization-based diagnostics at many levels. Potential customers include diagnostic companies, as well as microarray product companies. PdxBio offers services for design and analysis of DNA-based experimental platforms that are applicable to a number of market segments. For companies using microarrays, PdxBio can greatly facilitate overall program objectives because of its expert knowledge of DNA biophysics

Precision Haemostatics, Inc
Precision Haemostatics, Inc. (PHI) was formed for several reasons. Foremost, the purpose of the company is to get a patented test to market so that it can benefit patients, cost effectively, while generating revenue. The company is an extension of our entrepreneurial personality to use our own creativity, knowledge, planning, innovation, experiences, professionalism, and networking to bring to market a test that will benefit patients and create our own financial independence. We now envision many more applications for the test than we had originally planned. The Technology involved is novel and replicates the physiology of bleeding and clotting. Since blood flow is incorporated into the test, the company name imparts a connotation of blood flow.The Platelet-Stat™ Test System: The Platelet-Stat™ Test System is a patented test designed to physiologically measure primary hemostasis. Primary hemostasis (the initial stage of clotting) is the interaction of platelets (the clotting cell) with the vessel wall.Oncologists, Hematologists, Surgeons, Anesthesiologists, Cardiologists, and Blood Centers will want this test to diagnose bleeding, monitor medications and platelet transfusions, and detect microvascular bleeding in surgery. The test will reduce medical costs, assure optimal platelet transfusions, and monitor bleeding that may result from certain medications; thus decreasing adverse effects to the patient and again decreasing costs.

RxGen
RxGen, Inc. is a specialty preclinical service provider offering advanced non-human primate research services and outsourced R&D capabilities to the global pharmaceutical and biotechnology industries. RxGen employs clinically relevant models of human diseases to help clients rapidly assess and validate the safety and efficacy of therapeutics and novel biomedical technologies. RxGen can rapidly design and execute standard or custom research protocols for clients that result in outcomes more representative of human risk and response, significantly improving the subsequent investment decision making process. RxGen is actively seeking fee-for-service and collaborative R&D opportunities related to therapeutic and/or technology validation.

SELmedia, Inc.
SELmedia, Inc. produces and distributes evidence-based social emotional learning and character education programs to schools, professionals and parents. Developed by experts in developmental psychology and curriculum development, all programs offered by SELmedia are designed and tested to reduce school violence, increase children's social-emotional competence and character development and strengthen families and communities. The company provides on-line and on-site training for its programs and offers a web-based subscription model for customers.

Semandex Networks, Inc.
Semandex is the pioneer provider of Semantic Networks, the fastest, most cost-effective way to access, distribute and make sense of strategic information in real-time. Users not only find the information they need regardless of format or location, but are also updated of changes as they occur. Semandex enables: Access: to heterogeneous information sources; Updates: delivered to interested users in real-time; Intelligence: semantic links facilitate the analysis of data dependencies and interactions. Semandex customers include: Department of Defense, DHS, other government agencies, and telecom services providers among others. Semandex is seeking potential partners to further its growth.

SHOT
For nearly 20 years SHOT has been a technology incubator that develops innovative products for various customers. SHOT recently began licensing and spinning off its more promising products to its own start-ups. IKOtech, LLC is a SHOT spin-off company that provides high-throughput immunology-based magnetic cell sorting and analysis products for research, clinical diagnostic and cellular therapeutic applications. IKOtech's products hold competitive advantages in processing speed, capacity, and reduced cellular damage over current technologies. After benefiting from nearly $2.0 million in combined product development funds from SHOT and NIH, IKOtech is seeking a $5.0 million equity investment to execute its business plan.

Simbex
Simbex is a research and product development company with expertise in biomechanical feedback systems and medical device development. Our products and services are in the areas of rehabilitation, mobility, and sports injury prevention. Technical expertise includes orthopedic biomechanics, microelectronics, data acquistion and large-scale data reduction and analysis and materials. Business expertise includes strategic product development and market launch. Simbex takes product development from conceptualization through market launch, as needed, or partners with others with significant expertise that leverages Simbex's capabilities. Typically, we bring those products to market by driving the development to maturation and then partnering with industry leaders for the final commercialization phase. Simbex is a privately held New Hampshire Limited Liability Corporation.

SomaGenics, Inc.
SomaGenics focuses on translating important discoveries in RNA into products. Our lead product, an shRNA therapeutic to treat hepatitis C, is in development. Proof of concept for a second RNA product, for treatment of psoriasis, is proceeding in parallel with co-development of a new device to facilitate RNA delivery through the skin. Success in this program will enable our own products and those of other companies through sub-licensing arrangements. SomaGenics is also developing its foundational technology, the RNA Lasso, as a platform for diagnostic applications. This technology is uniquely capable of combining high sensitivity with high selectivity and multiplex capabilities.

SpectroCon LLC
SpectroCon is an innovative medical device development company focused on wound healing. Our main product, AutoFlow, is used to treat venous congestion, a serious complication of reconstructive microsurgery in which replanted tissue becomes congested with blood. Currently, when surgical repair of congested tissue is not feasible or successful, the only available treatment is the use of live, medicinal leeches. SpectroCon is also developing a new medical device that will assist in the healing of chronic wounds that can result from tissue injury or reconstructive surgery, and can subsequently cause tissue loss, infection, delayed healing, and increased scarring.

Systems Technology, Inc
Systems Technology, Inc. (STI) is a small (30 employee) research and development (R&D) company specializing in systems involving autonomous vehicles and human-machine interaction. We do contract research on problems involving automobile driving and aircraft piloting. As part of this work we have developed driving simulation technology that is useful for R&D, training and assessment applications. R&D work in driving simulation technology has spanned four decades at STI. We have had NIH SBIR/STTR contracts to develop the driving simulation technology for a range of training and assessment applications, and have pursued research experiments to validate these applications. Under our NIH-CAP program we are pursuing Pharmaceutical applications where affordable driving simulation technology can be used to determine both the beneficial and side effects of drug therapies. The simulation technology is currently being used by two drug companies for pre-clinical trials of ADHD and RLS medications.

The Virtual Reality Medical Center
The Virtual Reality Medical Center specializes in developing computer simulation and virtual reality systems to facilitate medical therapy. The products that VRMC is currently offering range from various pain management scenarios to clinically validated anxiety treatments. VRMC is promoting its first commercialized consumer product for pain management on the cell phone platform - an anytime/ anywhere solution to the problem of chronic pain management. This innovative, copyrighted software is currently the only 3D interactive product in this space.

Tiranoff Productions LLC/GeneticaLens
GeneticaLens is an information services company specializing in providing clinical quality documentation of rare and difficult to diagnose medical disorders. GeneticaLens systematically records moving visual images of symptoms and behaviors, providing critical comparative data to assist health care providers, as well as researchers worldwide in the difficult but essential enterprise of correctly identifying rare and difficult-to-diagnose diseases and genetic disorders. These recorded motion pictures, combined with a thorough database of information and expert interviews, will facilitate the recommendation of appropriate and timely treatments and therapies helping to improve the quality of life for individuals with these often devastating disorders.

VeriSci Corp
The company has developed a unique medical instrument, Neucodia, with patented automated icVEP technology, for the early detection and monitoring of eye diseases, particularly glaucoma. Using a direct-sales strategy, VeriSci will lease Neucodia to eye-care professionals. Each system will generate revenue on a per test basis. Glaucoma is one of the leading causes of blindness. Since these patients usually do not have symptoms in the early stages and the progressive neural damage is irreversible, early detection that leads to early treatment is critical. Conventional test procedures, such as intraocular pressure and visual field measures are not sensitive to early glaucomatous damage. The user-friendly device, Neucodia, can provide an accurate and non-invasive measure to aid in glaucoma diagnosis in a clinical environment. The potential market size in the US is $430M annually.

Vivalog Technologies
Vivalog Technologies (www.vivalog.com) is a provider of knowledge management software to hospitals and research institutions. Vivalog's web applications such as MyPACS.net are used by thousands of institutions around the world. Our core expertise is in applying the latest collaborative web technologies (Ajax) towards improving clinicians' ability to share and manage medical images. Vivalog's products help our customers maximize their return on investment in digital imaging and clinical information systems. Our software complements the PACS with new functionality for decision support, training and research.

VivaScan Corporation
VivaScan Corporation has developed a painless testing device for blood glucose monitoring by means of unique noninvasive infrared technology. Currently diabetic individuals stab themselves up to ten times per day to determine their blood glucose, or inject insulin blindly at considerable risk of complications. VivaScan's monitor, designed by a team of technical and clinical experts, responds to the noninvasive test needs of diabetic persons. A proprietary platform technology has evolved resulting in a personal hand held monitor. With the patented VivaScan glucose tester, a simple and gentle squeeze of the ear or finger is all it takes to get an accurate reading of blood glucose.

WinProbe Corporation
WinProbe Corporation is a medical ultrasound imaging research company specializing in elastography and optoacoustics. Product offerings will begin in 2008 of compact grayscale, color flow imaging system capable of real time mapping of the strain modulus of tissue and capable of imaging and differentiating the blood pool by vessel size, location and oxygenation level.

Xactagen, LLC
Xactagen's scalable technology validates gene targets and derives high-quality drug candidates in a fraction of the time required by traditional methods. We transform disease-relevant gene and protein data, derived from genomics and proteomics, into high-content (whole genome) drug discovery assays that use human cells. These include extensive libraries of gene expression reporter cells amenable to high-throughput drug discovery, high-throughput siRNA screening, and whole animal bio-imaging. We also generate mutant human cells for discovery of “personalized” medicines. Xactagen currently licenses our assays and participates in drug discovery alliances. We seek investment funding for our ongoing drug discovery programs.

Northern California

Aether Wire & Location, Inc.
Aether Wire is developing a single-chip Ultra-WideBand transceiver for low-power communication and location in mobile ad-hoc networks. The Aether Wire UWB transceiver provides unique features to enable new applications. Current applications include personnel tracking for Dismount Solders, Firefighters/Public Safety, and Medical/Emergency Response. The targeted mass market for our technology includes Wireless Sensor Networks. The Company is seeking $10 million to accelerate development of single-chip Localizer targeted at the mass market.

Argos Tech, LLC
Argos Tech, LLC is a start-up technology company pioneering mid-infrared semiconductor lasers. These lasers will replace gas lasers and other complex light sources in the $900 million market for analytical and industrial sensors and various emergent biomedical, homeland defense and military applications. The mid-infrared wavelengths constitute a “sweet spot” for optical gas detection. At these wavelengths, sensors gain in sensitivity by factors of 10 to 10,000, over present solutions. Today all commercially available systems for detecting trace gases with extreme sensitivity are large, expensive, appliances. Our lasers will enable the same sensitivity with handheld, relatively inexpensive, user-friendly, i-Pod-like sensors.

Bottlenotes, Inc
Bottlenotes is a customized wine club service for U.S. consumers seeking to enhance their appreciation of wine. Bottlenotes' service is unique in that club members' shipments are customized to their personal taste, and all information on the contents of each shipment is automatically stored in each member's personal "Virtual Cellar." All registered users can track wines that they taste via their Virtual Cellar and share this information with their Bottlenotes Friends. With its cutting-edge matching and Virtual Cellar technology, coupled with rich, proprietary content and most importantly, killer wines, Bottlenotes is poised to become the first premium online wine community.

Industrial Origami, Inc.
Industrial Origami, Inc (www.industrialorigami.com) based in San Francisco, enables green design and manufacturing innovation through its suite of manufacturing technologies that fundamentally change the way many consumer and industrial products are made. IOI's patented sheet material precision folding technology is licensed to companies to allow very significant cost savings and performance improvements over traditional design and manufacturing processes. Products incorporating the IOI technology are already in production. The market opportunity is very large affecting many types of manufactured products. IOI is currently focusing the application of its technology in electrical enclosures, appliances, electronic enclosures (computers, telecom) and autos. The IOI technology works with existing Computer Aided Design tools and existing capital equipment. This significantly reduces design-in costs for customers.

PARC (Spinout)
This company which is a spin out from PARC will design and develop, manufacture, and market an ink jet imager for PCB fabrication utilizing Xerox and PARC proprietary ink jet technology. The solution offers significant competitive advantage by allowing conventional PCB materials to be imaged in a digital manner at high throughput. Company revenues include a significant contribution from the sell of the consumable which functions as a mask during the PCB fabrication process. The business model includes revenue from sale of the imager, material and maintenance contracts.

PathoTect
PathoTect offers unique specific, rapid and sensitive detection of DNA. A hand-held detector provides real-time nucleic acid detection at the site of sampling. Large market opportunities in medicine, environmental monitoring and biodefense motivate our detection products. PathoTect technologies are faster, safer and accurate than today's solutions. Our product integrates collection, detection and diagnosis into an end-user operated device.

Seralogix, LLC.
Seralogix is a systems biology bioinformatics company providing advanced computational and modeling software tools and services to the pharmaceutical, medical and veterinary industries. Advanced tools for systems biology will be essential for making medical breakthroughs in the 21st century. Researchers need to make sense out of massive amounts of genomic and proteomic information in order to discover disease mechanisms leading to the development and evaluation of new intervening drugs, vaccines and diagnostics. Seralogix provides our customers with unprecedented discovery capability into disease mechanisms and interventions, helping guide and accelerate the development of new drugs, vaccines, and diagnostics through all stages of the development cycle -- from the Petri dish to personalized medicine.

Standard Biodiesel Inc
Biofuel is not standardized and this multi-billion dollar market is growing. Standard intends to produce, market, sell and ship proprietary anti-oxidant biofuel additive products and out-license some of the Company's platform biofuel manufacturing technology to other companies. The Company plans to market and sell licenses to certain parts of its biofuel manufacturing platform technology, including licenses with up-front technology access fees, milestone and royalty payments. The Company is enabling the standardization and stabilization of higher quality and more uniform biofuels derived from animal fat or plant oil feedstocks. This includes diesel-, gasoline, kerosene- and jet-fuel derived from plant oil. Standard has developed a biodiesel manufacturing process using plant feedstock oils containing variable and high concentrations of free fatty acids and can separate and recover high value feedstock oil byproducts. The Company's technology enables greater profit margins from a higher commercial grade, less variable and more stabile biofuel. The Company's management team has expertise in anti-oxidant and biofuel chemistry, natural product separation and recovery, and biofuel manufacturing, storage, and distribution. The Company's management team also has significant business, finance and technology out-licensing experience and considerable cumulative previous transactions. The Standard technology enables production of more profitable biofuel with uniform and stable composition and combustion profiles

Taiji Biomedical
Taiji Biomedical offers a unique biotech opportunity, joining limited risk with a high upside potential. Taiji's highest priority is to gain FDA approval within 4 years for its lead product for amyotrophic lateral sclerosis (ALS) with an investment of less than $10M. The compound, strongly protected by worldwide patents, is the first in a series of innovative small molecule therapeutics that acts against a novel target: abnormal, disease-causing macrophages in patients with neurodegenerative diseases. The projected cumulative sales are $1 billion two years after market introduction. ALS is a stepping stone to the much bigger market for Alzheimer's and other neurodegenerative diseases.

Teaching Machine, Inc.
Teaching Machine is a California corporation with elegant, interactive, voice-activated, multimedia software to teach language fluency. The first product, for teaching English reading and speaking uses a sophisticated speech processing technology that can “listen, analyze and correct” like a human teacher. An artificial intelligence approach combines a) the customization of the software for use by adults and children with a wide range of proficiency, b) an automated content upload system that converts any published content into curriculum, and c) a real-time comprehensive performance assessment system. The core innovation lies in the product's scalability, allowing for “one

product, many markets” concept.

Russia/Ukraine

Attometrix Ltd.
Attometrix Ltd. developed a new analytical platform for in vitro diagnostics (IVD). The combination of synthetic polymers, bio-molecules, NANO-particles and electrochemical biosensors allow IVDs to be used at the point of care and for field measurements in environmental, veterinary, medical and for antiterrorist application. Advanced Attometrix technologies helps to spend rapid and sensitive monitoring of neurotoxins, key metabolites and quantitative multimodal immunodiagnostics measurements using simple and low-cost IVD devices. Attometrix systems are currently successfully used for neurotoxins monitoring in water supply stations and food safety control.

BIOCHIP-IMB Ltd.
BIOCHIP-IMB manufactures three-dimensional, gel-based biochips for medical diagnostics and many other applications. The technology has been developed and patented, and it has several unique features which make it highly competitive on the current market. In Russia, most widely used and certified are the “tuberculosis biochips” that are able to detect TB agent and define its sensitivity to anti-TB drugs. Other biochips allow to detect the flu-causing agent, including avian flu, to perform personal identification, to identify chromosomal mutations correlated with cancer of different type, etc. Due to low cost, our biochips are meant for large scale screening of high risk groups in the population.

International Center for Electron Beam Technologies
The International Center for Electron Beam Technologies (ICEBT) of the E.O.Paton Electric Welding Institute of the Ukrainian National Academy of Sciences is an independent legal entity involved in research and development activities. The ICEBT has its own bank accounts in Ukraine and abroad, and has the right to sign contracts directly with both foreign public organizations and private companies. ICEBT`s activity focuses on the research and development of technologies and equipment for high-rate electron-beam evaporation and deposition of substances in vacuum and investigation of their structures and properties. ICEBT also develops advanced materials and coatings of a specified composition, as well as researches their structure and properties. ICEBT has a staff of 40 of which ten are doctors of science.

Kinetic Technologies Ltd. (Kintech)
KINTECH (Kinetic Technologies) is a well-established R&D company developing and distributing innovative scientific software products in the field of modeling physical and chemical processes and materials. Kintech is also conducting intensive research projects and consulting services in the following areas: microelectronics, advanced materials and nanotechnology, plasma processing, energy systems and hydrogen energy, environment protection and industrial safety. The main features of the KINTECH modeling approach and software are model-based assimilation of fundamental theoretical and experimental data, multiscale, multiphysics first-principles-based modeling (from atoms and electronic structure methods to device and reactor engineering analysis) and development of integrated virtual modeling systems supporting research projects.

Nanocenter
NanoCenter conducts research focused on the development of bulk nanostructured materials for advanced applications using severe plastic deformation (SPD). Currently, NanoCenter is conducting in-depth research on several aspects of SPD, including the development of SPD processing methods and studies on the structural, mechanical and functional properties and performance of SPD-processed nanomaterials. We are particularly focused on the practical applications of bulk nanostructured materials in the mechanical and aerospace engineering and medical fields. These works are carried out in close cooperation with Russian and international research centers.

Sarov Laboratories
Sarov Laboratories is the premier Russian innovative outsourcing services provider, a spin-off of the Federal Nuclear Center VNIIEF in Sarov, Russia. In the second half of the 20th century, the Federal Nuclear Center, a Russian nuclear lab, hired the brightest scientists and engineers from all over the country. As a result, the staff at SarovLabs possesses excellent scientific and engineering backgrounds as well as extensive expertise in solving a wide range of complex applied problems. In addition, the company's cost-effective project management environment ensures that high-tech projects are completed quickly with quality results.

Southern California

Alexion Antibody Technologies
San Diego-based Alexion Antibody Technologies (AAT) discovers and develops antibody therapies. We have a broad pipeline of new drug candidates and programs for cancer, infectious and autoimmune diseases, created from powerful antibody discovery platforms. AAT's lead antibody, ALXN6000 is an anti-CD200 blocking therapy which targets a key immunosuppressive protein expressed on the surface of cancer cells. Clinical trials for CLL will be initiated in 2007, with the opportunity to extend to a broad range of cancers. AAT has also developed a powerful antibody-based therapeutic drug/vaccine platform to treat chronic infectious diseases, and autoimmune diseases, based on exclusive rights to two high-value immune cell receptors.

Algoryx, Inc.
Algoryx patented algorithms and software enable design and manufacturing companies to accomplish better, faster, cheaper New Product Development and higher quality, lower cost Production. The algorithms use advanced statistical, correlation, regression, mapping and decision-making technologies. The Correlation Master™ computational software replaces trial-and-error, iteration and guesswork with scientific methods that generate breakthrough insights and solutions for design, tooling, process and quality engineers. Algoryx domestic and international customers are industry leaders in the automotive, computer, fluid management and medical device industries. The technology applies to a wide range of manufacturing processes from plastic injection molding to metal forming to semiconductor wafer fabrication.

Ambryx Biotechnology
Ambryx Biotechnology Inc. is an emerging biotech company dedicated to bringing innovative cancer and obesity therapeutics to the market. Its portfolio of bioactive peptides have shown to be highly effective in the laboratory and clinical pilot studies. These peptides are non-toxic, naturally occurring peptides derived from animal serum and milk using a patent-protected process. Ambryx bioactive peptides can be further isolated to become pharmaceutical drugs or sold in their current form as dietary supplements.

XCOR Aerospace
XCOR Aerospace is a California corporation located in Mojave, California. The company is in the business of developing and producing safe, reliable and reusable rocket engines, rocket propulsion systems, and rocket powered vehicles.

Taiwan

AirDio Wireless Inc.
AirDio Wireless (www.airdio.com) is an emerging company with the vision of building RFIC / RFSiP (System-In-Package) Module Parametric Tester/Handler and wireless networking device RF System Tester for the emerging voice, data and video services supporting ubiquitous communications in the fast growing wireless networking market. The company's innovative WiFi Parametric/System integrated test platform reduces test time, improves reliability and reduces tester cost significantly. The tester also introduces Strip Test Handler to improve yield rate and modular design to enhance scalability for future expansion.

IAdea Corporation
IAdea Corporation develops world's first peer-to-peer IP media transport silicon chip and management middleware. During the announcement at CES 2007, our product attracted over 16,000 web pages reporting the new technology and inquiries from telecom companies worldwide. Our technology enables new-generation IP media (IPTV, STB, digital signage, corporate TV, retail TV) operators to build networks that are infinitely scalable and can be constructed at a tiny fraction of the cost of a traditional IPTV data center. Our technology will create a commercial value in the billions of dollars per year and bring great returns to shareholders.

OleMap Inc.
Established in 2000, OleMap has been the technology leader in providing internet local search and mobile location based solutions in Greater China. OleMap's core competence lies in its technical capability in the emerging field of IT and Wireless Communication, and knowledge in Spatial Information System. These capabilities are further demonstrated by launching the best local search website in the region, www.urmap.com, a carrier grade mobile location based service platform, OleSpot, and various location based software, UrMap Mobile and Location Notes, for mobile devices.

United Biomedical, Inc., Asia
United Biomedical, Inc., Asia (UBIA) is a subsidiary of United Biomedical, Inc. (UBI), a Delaware corporation headquartered in New York. UBI is a multinational bio/pharmaceutical firm dedicated to the discovery and development of a new class of immunotherapeutics and vaccines for chronic and infectious diseases. This new class of biologicals, based on UBI platform technologies, has great potential with applications in a wide range of therapeutic areas. UBI has three subsidiaries located in Beijing, Shanghai, and Taiwan, with around 300 associates (full-time), the majority of whom have advanced degrees or extensive professional experiences in the bio/pharmaceutical industry.

XCome Technology Ltd.
XCome is a world leader in creating software applications for telecommunications operators and handset manufacturers. XCome has a comprehensive and user-friendly series of mobile instant messaging solutions. As a Microsoft WLM ISV member, we enable mobile carriers to provide a superior customer-recognized MSN (WLM) client user experience. XCome offers a mobile unified messaging client together with a content management server. With centralized contact management, messenger, e-mail, blog, search, and other related features, this complete solution empowers mobile users to stay in touch with their contacts and instantly share their experiences.

Tech Transfer Pavilion

Pivotal BioSciences
Pivotal BioSciences, Inc. is an emerging company dedicated to the development and commercialization of innovative cancer therapies. Breakthroughs in the basic understanding of the immune system, combined with powerful new biotechnological tools, have provided the foundation for new, rational, and technologically sophisticated approaches to immunotherapy. In the mid-'90s when it became apparent that cancer tumor growth is angiogenesis-dependent (new blood vessel formation), scientists began to understand the mechanisms by which tumor growth is stimulated by angiogenesis. Pivotal BioSciences is pioneering the effort to develop powerful new compounds to control this process and thereby cut off the blood supply to growing tumors.

Sun BioMed, Inc.
Sun BioMed is a UCLA faculty biotechology start-up company, eatablished a novel in situ drug delivery platform with applicability to siRNAs, genes, biologics & small molecules. The mechanism is entirely distinct from conventional electroporation and has been shown to be safe and efficient in vivo. Prototype devices for cardiac, orthopaedic and hepatic delivery developed and tested in vivo. Core platform patent issued in 2003 (U.S. 6,593,130) with pending applications on specific devices and methods of use.

The Research Institute at California Pacific Medical Center
California Pacific Medical Center Research Institute (CPMCRI) is the research arm of California Pacific Medical Center (CPMC), the largest medical center in San Francisco. CPMC is a not-for-profit academic quaternary care hospital, affiliated with Sutter Health, the largest health care system in northern California. Major areas of laboratory-based investigation include cancer, neurobiology, cell biology, gene therapy, and infectious diseases. Major areas of investigator-initiated clinical research include women's health, longevity, pharmacokinetics of substance abuse, neurodegenerative disorders and behavioral medicine. In addition, CPMCRI has an active clinical trials program, with an emphasis in hepatology, transplantation, cardiovascular diseases, and oncology.

West Coast

Aestis Inc.
Aestis is a spin out company from Colorado Altitude Training, the world's leader in altitude simulation, that has developed a medical breakthrough for the treatment of obesity through controlled hypoxia technology. The ThinAir™ system will be the first non-invasive, non-pharmacological product to treat and prevent obesity which does not require diet and exercise. Aestis' focus is on obtaining regulatory approval to market the proprietary system in the United States and Europe in the next three years.

Radiant Metrics, Inc.
Radiant Metrics, Inc., a spin-out from pattern recognition experts RAF Technology, provides a software solution that locates, extracts, and quantifies data for the investment management and related industries. With an innovative search approach, applying proven pattern recognition technology, we are turning unstructured data into relevant, actionable intelligence to help investment managers make better decisions.

Spry Learning Company
Spry Learning develops smart games as part of a comprehensive brain fitness program used for prevention of cognitive decline. Spry's games help boomers reduce their risk for Alzheimer's disease and other forms of cognitive impairment by exercising their minds by playing highly adaptive games, keeping them optimally stimulated and delivering the maximum impact in the shortest amount of time.